1,200-IU dose of vitamin D3<\/sub> supplementation tied to decreased risk for psychiatric symptoms at ages 6 to 8 years versus 400-IU dosing<\/p>\n<\/h3>\n By Lori Solomon HealthDay Reporter<\/b><\/p>\n <\/b><\/p>\n WEDNESDAY, May 24, 2023 (HealthDay News) — Higher doses of vitamin D3<\/sub> supplementation up to age 2 years are associated with a decreased risk for internalizing problems in later childhood, according to a study published online May 19 in JAMA Network Open<\/em>.<\/p>\n Samuel Sandboge, M.D., Ph.D., from the University of Tampere in Finland, and colleagues conducted a secondary analysis of a randomized clinical trial of 346 children to assess the impact of high-dose (1,200 IU) versus standard-dose (400 IU) vitamin D3<\/sub> supplementation during the first two years of life on psychiatric symptoms at ages 6 to 8 years.<\/p>\n The researchers found that clinically significant internalizing problems occurred in 5.6 percent of participants in the 1,200-IU group versus 11.8 percent in the 400-IU group (odds ratio, 0.40), when adjusting for sex, birth season, maternal depressive symptoms at birth, and parental single status at follow-up. Among 48 children in the 400-IU group with maternal 25(OH)D concentrations <30 ng\/mL, higher internalizing problems scores were seen compared with children in the 1,200-IU group, including 44 children with maternal 25(OH)D concentrations <30 ng\/mL (adjusted mean difference, 0.49) and 91 children with maternal concentrations >30 ng\/mL (adjusted mean difference, 0.37). No differences were seen between the groups for externalizing or total problems.<\/p>\n “This should be interpreted cautiously, however, and be considered only as hypothesis generating given the absence of interactions between maternal 25(OH)D level and supplementation status,” the authors write.<\/p>\n One author reported receiving grants from the Novo Nordisk Foundation.<\/p>\n